Acute heart failure with low cardiac output: can we develop a short-term inotropic agent that does not increase adverse events?

Current Heart Failure Reports
Umberto CampiaMihai Gheorghiade

Abstract

Acute heart failure represents an increasingly common cause of hospitalization, and may require the use of inotropic drugs in patients with low cardiac output and evidence of organ hypoperfusion. However, currently available therapies may have deleterious effects and increase mortality. An ideal inotropic drug should restore effective tissue perfusion by enhancing myocardial contractility without causing adverse effects. Such a drug is not available yet. New agents with different biological targets are under clinical development. In particular, istaroxime seems to dissociate the inotropic effect exerted by digitalis (inhibition of the membrane sodium/potassium adenosine triphosphatase) from the arrhythmic effect and to ameliorate diastolic dysfunction (via sarcoendoplasmic reticulum calcium adenosine triphosphatase activation). Additionally, the myosin activator omecamtiv mecarbil appears to have promising characteristics, while genetic therapy has been explored in animal studies only. Further investigations are needed to confirm and expand the effectiveness and safety of these agents in patients with acute heart failure and low cardiac output.

References

Feb 9, 2002·American Journal of Physiology. Heart and Circulatory Physiology·Toshio SagawaJ Andrew Wasserstrom
Mar 28, 2002·JAMA : the Journal of the American Medical Association·Michael S CuffeUNKNOWN Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigato
May 15, 2002·Progress in Cardiovascular Diseases·Eric J Eichhorn, Mihai Gheorghiade
Jul 23, 2002·Lancet·F FollathUNKNOWN Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study
Sep 18, 2002·Journal of Molecular and Cellular Cardiology·Gerd Hasenfuss, Burkert Pieske
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·R MichelettiP Ferrari
Dec 18, 2002·American Heart Journal·Andrew J BurgerUNKNOWN Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy
Jan 9, 2003·JAMA : the Journal of the American Medical Association·Margaret M RedfieldRichard J Rodeheffer
Feb 28, 2003·The Journal of Pharmacology and Experimental Therapeutics·M RocchettiA Zaza
Mar 26, 2003·Journal of the American College of Cardiology·G Michael FelkerUNKNOWN OPTIME-CHF Investigators
Mar 16, 2004·Circulation Research·Xander H T WehrensAndrew R Marks
Jun 24, 2005·Proceedings of the National Academy of Sciences of the United States of America·Xander H T WehrensAndrew R Marks
Sep 27, 2005·The American Journal of Cardiology·Markku S Nieminen, Veli-Pekka Harjola
Dec 21, 2005·Circulation·Mihai GheorghiadeUNKNOWN International Working Group on Acute Heart Failure Syndromes
Jun 1, 2006·Circulation·Mihai GheorghiadeWilson S Colucci
Nov 9, 2006·JAMA : the Journal of the American Medical Association·Mihai GheorghiadeUNKNOWN OPTIMIZE-HF Investigators and Coordinators
Dec 19, 2006·Journal of the American College of Cardiology·Emil M deGomaEuan A Ashley
May 3, 2007·JAMA : the Journal of the American Medical Association·Alexandre MebazaaUNKNOWN SURVIVE Investigators
May 15, 2007·Journal of the American College of Cardiology·Cheuk-Man YuJae K Oh
Jan 28, 2009·Circulation·Donald Lloyd-JonesUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Feb 24, 2009·Heart Failure Reviews·John R Teerlink
Apr 3, 2009·The New England Journal of Medicine·Stephen F JencksEric A Coleman

❮ Previous
Next ❯

Citations

Jun 7, 2011·American Journal of Therapeutics·Hauke Fuerstenwerth
Jun 21, 2016·Canadian Journal of Physiology and Pharmacology·Péter NánásiZoltán Papp
Aug 3, 2019·Journal of the Saudi Heart Association·Waleed AlHabeebWalid Hassan
Jan 7, 2020·Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing·Leonardo CalòAntonio D'Onofrio
Nov 21, 2017·ESC Heart Failure·Pramodsingh H ThakurRoy S Gardner

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.